Search Results - "Mercadé, T. Macarulla"

A phase 1b multicenter, open-label study of investigational TAK-228 (MLN0128) plus TAK-117 (MLN1117) in adult patients with advanced nonhematologic malignancies by Juric, D, Lopez, J, Rasco, D, Macarulla Mercadé, T, Xu, Q, Brittany, B, Kuida, K, Patel, C, Neuwirth, R, Enke, A, Zohren, F, Burris, H.A

“…Background: Sustained monotherapy of selective mTOR kinase inhibitors (mTORi) such as TAK-228 may be limited by pathway reactivation via feedback signaling…”
Get full text

Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial by Mercadé, T. Macarulla, Lee, K., Lakatos, G., Wang-Gillam, A., Chen, L., Mirakhur, B., De Jong, F.

Get full text

Symptoms at diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine practice and frequency variation across Europe by Carrato Mena, A., Melisi, D., Westphalen, B., Mellbring, Å.B.C., Taieb, J., Prager, G., Macarulla Mercadé, T., esquermes, N.D., Ferreras, A., de Jong, F.

Get full text

Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study by Chen, L.-T., Macarulla Mercadé, T., Lee, K.-H., Lakatos, G., Wang-Gillam, A., Mirakhur, B., de Jong, F.

Get full text

Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial by Lakatos, G., Lee, K., Siveke, J., Blanc, J., Mercadé, T. Macarulla, Dean, A., Bodoky, G., Mirakhur, B., Chen, J., Wang-Gillam, A., Chen, L., de Jong, F.

Get full text

Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) by Lee, K., Bodoky, G., Blanc, J., Siveke, J., Mercadé, T. Macarulla, Wang-Gillam, A., Chen, L., Mirakhur, B., Chen, J., de Jong, F.

Get full text

Symptoms reported at initial diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine clinical practice and variation in frequencies across Europe by Melisi, D., Westphalen, B., àMellbring, Carrato, A., Taieb, J., Prager, G., Macarulla Mercadé, T., Esquermes, N D´, Ferreras, A., de Jong, F.

Get full text

Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe by Prager, G., Mercadé, T. Macarulla, àMellbring, Taieb, J., Carrato, A., Melisi, D., Westphalen, B., Esquermes, N D´, Ferreras, A., de Jong, F.

Get full text

Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) by Mercadé, T. Macarulla, Wang-Gillam, A., Chen, L., Blanc, J., Lee, K., Bodoky, G., Dean, A., Siveke, J., Mirakhur, B., Chen, J., de Jong, F.

Get full text

The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy by Mercadé, T. Macarulla, Wang-Gillam, A., Chen, L., Blanc, J., Lee, K., Bodoky, G., Dean, A., Chen, J., Mirakhur, B., Siveke, J., de Jong, F.

Get full text

Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe by Taieb, J., Carrato, A., àMellbring, Prager, G., Melisi, D., Westphalen, B., Mercadé, T. Macarulla, Esquermes, N.D´., Ferreras, A., De Jong, F.

Get full text

Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients by de Toro Carmena, M., Ortega Morán, L., García Adrián, S., Castañón López, C., Molina Villaverde, R., Marrupe González, D., Lopez Muñoz, A., Alcaraz Nunes, D., Díaz Beveridge, R., López Alfonso, A., García Paredes, B., Fernández Montes, A., Soriano Rodríguez, M., Encinas García, S., Alcaide García, J., Pericay Pijaume, C., Macarulla Mercadé, T., Rodríguez-Salas, N., García Alfonso, P., Muñoz Martín, A.

Get full text

A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results by Chiritescu, G., Dumon, K., Mercadé, T. Macarulla, Lang, I., Vivas, C. Santos, Papai, Z., Janssens, J., Hendrickx, K., Pracht, M., Van den Eynde, M., Taïeb, J., Moons, V., Geboes, K., Van Laethem, J., Greil, R., Cervantes, A., Vergauwe, P., Ferrante, M., Vanderstraeten, E., Fridrik, M., Wöll, E., Limón, M., Rivera, F., Sagaert, X., Tejpar, S., Van Cutsem, E.

Get full text

First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe by Taieb, J., Carrato, A., Westphalen, B., Melisi, D., Prager, G., Macarulla Mercade, T., Mellbring, ÅB.C., d'Esquermes, N., Ferreras, A., de Jong, F.

Get full text

Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review (SLR) by Macarulla Mercade, T., Hendifar, A., Li, C.-P., Reni, M., Riess, H., Tempero, M.A., Dueck, A., Botteman, M.F., Deshpande, C., Lucas, E., Oh, D.-Y.

Get full text

NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) by Macarulla Mercade, T., Bodoky, G., Siveke, J., Lee, K.-H., Chen, J., Mirakhur, B., Dean, A., Chen, L.-T., de Jong, F.

Get full text

Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios? by Matos Garcia, I., Azaro, A., Viaplana, C., Hierro, C., Martin-Liberal, J., Brana, I., Gardeazabal, I., Gomila, P., Vieito Villar, M., Ochoa De Olza Amat, M., Elez Fernandez, E., Oliveira, M., Oaknin, A., Verdaguer, H., Navarro Mendivil, A., Alsina, M., Tabernero, J., Macarulla Mercade, T., Dienstmann, R., Garralda, E.

Get full text

1567TiP A phase III trial of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3 by Picozzi, V.J., Macarulla Mercadé, T., Philip, P.A., Becerra, C.R., Dragovich, T.

Get full text

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours by Powderly, J., Bendell, J.C., Carneiro, B.A., Italiano, A., Mercadé, T. Macarulla, Alvarez, E. Castanon, Imbimbo, M., Massard, C., Mueller, N., Gascó -Hernandez, A.

Get full text

200PLiposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study by Chen, L-T, Macarulla Mercadé, T, Lee, K-H, Lakatos, G, Wang-Gillam, A, Mirakhur, B, de Jong, F

Get full text